Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 07/26/23
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®Business Wire • 06/22/23
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty ProgramBusiness Wire • 06/08/23
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by SymateseBusiness Wire • 05/09/23
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateBusiness Wire • 03/08/23
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business UpdateBusiness Wire • 02/22/23
Evolus: Extra Strength Dose Data Provides Additional Offering Expansion For JeuveauSeeking Alpha • 02/07/23
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month PerformanceBusiness Wire • 01/28/23
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World CongressBusiness Wire • 01/23/23